Introduction {#Sec1}
============

Type 2 diabetes mellitus is characterized by an impaired insulin secretion in response to glucose stimulation \[[@CR1]\]. With ongoing disease duration, most patients show a progressive reduction in β-cell mass and deterioration in beta-cell function \[[@CR2], [@CR3]\]. Current treatment guidelines recommend the introduction of metformin at diagnosis in combination with diet and exercise as first-line therapy for type 2 diabetes \[[@CR4]\]. However, metformin does not prevent progression of type 2 diabetes over long term as consistently shown by the UK prospective diabetes study (UK-PDS) or a diabetes outcome progression trial (ADOPT) \[[@CR5], [@CR6]\]. Chronic hyperglycemia has harmful effects on glucose-induced insulin secretion and might accelerate apoptosis of β-cells \[[@CR7]\]. Furthermore, chronic hyperglycemia can deteriorate endothelial function \[[@CR8]\]. This glucotoxic effect became apparent if blood glucose concentration exceeds 6.4 mmol/l and is primarily associated with a deterioration of pulsatile insulin secretion and acute insulin response to a glucose load \[[@CR7]\]. Insulin therapy according to guidelines is usually introduced late in the course of the disease \[[@CR4]\]. However, recently published trials have demonstrated a sustained improvement of endogenous insulin secretion by early short-term exogenous insulin supplementation \[[@CR9], [@CR10]\]. In addition, an outcome trial with basal insulin glargine compared to standard care demonstrated a significant reduction in incident type 2 diabetes by 28 % in insulin-treated participants without diabetes at baseline \[[@CR11]\]. These results suggest that strict glucose control with early insulin treatment may protect β-cells from harmful effects of glucotoxicity. Long acting insulin analogs provide good glycemic control together with a low risk of hypoglycemia \[[@CR12]\]. The initiation of basal insulin treatment early in the course of the disease may help to minimize the required insulin dosage and therefore adverse effects on body weight \[[@CR13]\]. In contrast to metformin which cannot be used in several patients, for example, with advanced renal impairment, basal insulin may be used regardless of concomitant diseases \[[@CR14]\].

The aim of our study was to evaluate the effects of basal insulin glargine in patients with drug naïve type 2 diabetes (\<5 years) on quality of glucose control as well as on beta-cell function and microvascular blood flow in comparison with metformin.

Materials and methods {#Sec2}
=====================

Study protocol and patients {#Sec3}
---------------------------

Ninety-six patients were included into this multicenter, open-label, prospective study to receive either metformin at a target dose of 1,000 mg b.i.d. or insulin glargine once-daily at bedtime. Insulin dose was titrated stepwise to a target fasting glucose of ≤5.6 mmol/l according to a standardized titration schedule \[[@CR15]\]. All insulin-treated patients were instructed to assess their fasting blood glucose daily using the FreeStyle Lite^®^ (Abbott, Wiesbaden, Germany) and to adjust their insulin dose to target. In addition, all patients were asked to self-assess blood glucose if they experienced clinical symptoms of hypoglycemia.

Main inclusion criteria for the study were a drug naïve type 2 diabetes mellitus with \<5 years after diagnosis and a HbA1c between 6.5 and 8 %. Main exclusion criteria were renal dysfunction with a calculated glomerular filtration rate below 60 ml/min, acute or chronic diseases which could lead to tissue hypoxia, the use of intravascular contrast agents throughout the study, increase in serum transaminases more than 2.5-fold of the upper limit of the normal range, or systemic corticosteroid treatment. At baseline and after 36 weeks of treatment, all patients received a 72 h continuous interstitial glucose monitoring (CGM) with a standardized test meal at day 2 and a test of microvascular blood flow. All patients got a reinforcement of dietary counseling at study entry and throughout the study. Dietary records of the patients were analyzed by specialized staff at each visit date to prevent weight gain. The study protocol was approved by the ethics committee of the Saxony chamber of physicians. All patients gave written informed consent before inclusion.

Continuous glucose monitoring {#Sec4}
-----------------------------

We used the Medtronic System Gold™ Monitor with MiniMed glucose subcutaneous sensors (Medtronic MiniMed, Northridge, CA). The system is approved for a continuous measurement of interstitial glucose (IG) every 5 min over 72 h within the subcutaneous fat tissue. Analysis was limited to the data obtained from the intermediate 48 h of recording to avoid bias due to insertion and removal of the CGM. On the morning of the second day of CGM, a standardized test meal was consumed by the patients at the study site. The test meal consisted of 95 g whole-grain bread, 20 g margarine, 25 g jam, 25 g cheese, 200 ml orange juice, and 200 ml milk mix drink which corresponds to 50 % carbohydrates, 35 % fat, and 15 % proteins with a total energy content of 511 kcal.

For the assessment of glycemic variability, we calculated the overall area under the IG curve (AUC) and the incremental area under the glucose curve of the test meal (incAUC) and assessed the mean IG, standard deviation (SD) of IG, and mean average glucose excursions (MAGE). MAGE was calculated as the arithmetic mean of the differences between consecutive peaks and nadirs, provided that the differences are greater than one SD of the mean glucose value.

Laser-Doppler measurement of microcirculation {#Sec5}
---------------------------------------------

Microvascular skin blood flow has been assessed using Laser-Doppler fluxmetry (O2C, LEA Medizintechnik, Giessen, Germany) as described \[[@CR16]\]. The skin probe was placed at the dorsal thenar site of the left hand in between the phalanx of the thumb and metatarsal bone of the 2nd digit. Measurements were performed at 2 mm depth with a continuously emitted laser light (wavelength 830 nm). The movement of erythrocytes within the sample volume causes a Doppler shift effect of the laser light which allows for the calculation of the flow velocity and consequently the relative blood flow, which is expressed in arbitrary units (U). We measured the pre-ischemic blood flow (pBF) and the maximal post-ischemic blood flow (maxBF) during reactive hyperemia after 5 min of suprasystolic ischemia of the forearm. Average pBF was calculated over 4 min and maxBF was recorded as peak blood flow 20--40 s after cuff release. The same location of the skin probe was used for repeated measurements; patients rested at least 30 min in a quite temperature-controlled room prior to the start of the examination.

Biochemical analysis {#Sec6}
--------------------

HbA1c was measured chromatographically using HPLC (TOSOH G8, Stuttgart, Germany); insulin, proinsulin, and C-peptide were measured with EIA (TOSOH AIA 360, Stuttgart, Germany); triglycerides were measured with the GPO-PAP method; LDL and HDL cholesterol fractions were measured by enzymatic tests on the Konelab 20xTi (ThermoFisher, Dreieich, Germany).

Homeostasis model assessment was used to estimate basal beta-cell function (HOMA B) and insulin resistance (HOMA IR). HOMA B was calculated as 20 × fasting insulin/(fasting plasma glucose − 3.5) and HOMA IR as fasting plasma glucose × fasting insulin/22.5.

Statistical analysis {#Sec7}
--------------------

All continuous parameters are expressed as mean ± SD if not indicated otherwise. Not normally distributed variables were log-transformed. Student's *t* test for comparisons between treatment groups and paired *t* test for comparisons within a treatment group (i.e., first vs. last visit) were applied. The primary objective was the change of IG--AUC, and therefore, we performed a per protocol analysis. The calculated power for the primary objective was 78 %. Not normally distributed variables were analyzed using Mann--Whitney *U* test. Categorical variables were compared by chi square test. Differences of baseline variables between study groups were considered using an analysis of covariates (ANCOVA) for the evaluation of treatment effects. A *p* value \< 0.05 indicated statistical significant differences. All statistical analyses were performed using SPSS 19.0 software.

Results {#Sec8}
=======

Seventy-five out of 97 randomized patients finished the study per protocol. The dropout rate was identical between metformin (*n* = 5)- and glargine (*n* = 6)-treated patients. In 11 patients, CGM at the end of study could not be analyzed due to recording problems.

Baseline clinical parameters were well balanced between treatment groups (Table [1](#Tab1){ref-type="table"}). Interstitial glucose monitoring demonstrated a more pronounced reduction in mean IG and AUC with insulin glargine, whereas the reduction in the incremental AUC was comparable between treatments (Table [2](#Tab2){ref-type="table"}). However, after 36 weeks of treatment, we found nearly identical IG curves (Fig. [1](#Fig1){ref-type="fig"}) for insulin and metformin. Glycemic variability (expressed as MAGE or SD) at the study end was significantly higher with insulin glargine; however, the change from baseline was at the same range for both indices (Table [2](#Tab2){ref-type="table"}).Table 1Baseline clinical parametersMetformin (*n* = 36)Insulin (*n* = 39)*p*Sex female n (%)18 (50)13 (33.3)0.220Age (year)62.03 ± 9.460 ± 9.30.348Diabetes duration (year)2.6 ± 1.62.8 ± 1.40.602BMI (kg/m^2^)29.9 ± 5.329.2 ± 4.60.537Weight (kg)87.6 ± 17.987.6 ± 15.10.965Waist (cm)102.5 ± 14.5103.7 ± 11.10.678Systolic BP (Torr)141.5 ± 14.8141 ± 15.70.896Diastolic BP (Torr)81.2 ± 10.485.3 ± 9.80.133Table 2Glycemic parameter assessed by continuous glucose monitoring, biomarker of beta-cell function and biochemical parameterMetformin (*n* = 36)Insulin glargine (*n* = 39)*p*Parameter of glucose control FPG baseline (mmol/l)8.7 ± 1.69.2 ± 2.10.297 FPG week 36 (mmol/l)7.2 ± 16.1 ± 1.10.001 FPG change (mmol/l)−1.4 ± 1.5−3.1 ± 2.50.001 PPG 120′ baseline (mmol/l)10.3 ± 2.811.1 ± 4.50.415 PPG 120′ week 36 (mmol/l)8.4 ± 2.18.3 ± 2.50.832 PPG 120′ change (mmol/l)−1.6 ± 2.5−2.8 ± 3.20.106 HbA1c baseline (%)6.9 ± 0.47.2 ± 0.70.045 HbA1c week 36 (%)6.31 ± 0.46.36 ± 0.40.478 HbA1c change (%)−0.6 ± 0.41−0.8 ± 0.690.087Interstitial glucose measurements AUC baseline (mmol l^−1^ min)2387.0 ± 500.32671.5 ± 598.50.029 AUC week 36 (mmol l^−1^ min)1971.8 ± 337.82000.3 ± 313.10.774 AUC change (mmol l^−1^ min)−416.1 ± 537.6−671.2 ± 507.90.039 incAUC baseline (mmol l^−1^ min)55.4 ± 30.273.9 ± 39.90.027 incAUC week 36 (mmol l^−1^ min)49.6 ± 25.068.3 ± 24.60.002 incAUC change (mmol l^−1^ min)−5.8 ± 31.8−5.7 ± 40.40.989 Mean IG baseline (mmol/l)8.3 ± 1.79.4 ± 2.10.015 Mean IG week 36 (mmol/l)6.9 ± 1.27.0 ± 1.00.573 Mean IG change (mmol/l)−1.4 ± 1.8−2.4 ± 1.70.022 MAGE baseline3.3 ± 0.94.0 ± 1.10.001 MAGE week 362.9 ± 1.13.7 ± 1.00.001 MAGE change−0.4 ± 1.7−0.3 ± 1.30.676 SD baseline1.6 ± 0.81.8 ± 0.60.121 SD week 361.3 ± 0.51.7 ± 0.50.001 SD change−0.2 ± 0.7−0.07 ± 0.70.45Parameter of beta-cell function Proinsulin 0′ baseline (pmol/l)8.6 ± 6.213.0 ± 13.50.023 Proinsulin 0′ wk 36 (pmol/l)5.8 ± 4.65.4 ± 5.00.35 Proinsulin 0′ change (pmol/l)−3 ± 4.1−7.6 ± 10.80.001 Proinsulin 120′ baseline (pmol/l)26.8 ± 16.037.8 ± 32.20.069 Proinsulin 120′ week 36 (pmol/l)20.4 ± 19.926.8 ± 290.259 Proinsulin 120′ change (pmol/l)−6.6 ± 14.3−11.1 ± 26.80.019 C-peptide 0′ baseline (nmol/l)1.0 ± 0.50.9 ± 0.40.453 C-peptide 0′ week 36 (nmol/l)0.9 ± 0.40.5 ± 0.30.001 C-peptide 0′ change (nmol/l)−0.1 ± 0.3−0.4 ± 0.40.001 C-peptide 120′ baseline (nmol/l)2.7 ± 1.12.4 ± 1.00.274 C-peptide 120′ week 36 (nmol/l)2.6 ± 1.32.2 ± 1.00.274 C-peptide 120′ change (nmol/l)0 ± 0.7−0.2 ± 0.80.348 Insulin 0′ baseline (pmol/l)90.6 ± 51.285.1 ± 48.60.733 Insulin 0′ week 36 (pmol/l)71.6 ± 43.0104.4 ± 62.90.01 Insulin 0′ change (pmol/l)−19.2 ± 26.019.2 ± 47.90.001 Insulin 120′ baseline (pmol/l)445.2 ± 303401.8 ± 296.20.487 Insulin 120′ week 36 (pmol/l)364.6 ± 285448.8 ± 371.90.416 Insulin 120′ change (pmol/l)−79.9 ± 216.946.6 ± 275.60.06 Insulin/proinsulin 120′ baseline22.2 ± 29.112.5 ± 7.50.063 Insulin/proinsulin 120′ week 3624.7 ± 27.120.7 ± 11.80.410 Insulin/proinsulin 120′ change3.0 ± 8.48.2 ± 9.40.015 HOMA B baseline49.4 ± 34.548.2 ± 36.70.893 HOMA B week 3656.3 ± 34.5128 ± 990.001 HOMA B change4.4 ± 19.577.2 ± 97.80.001 HOMA IR baseline5.0 ± 3.74.9 ± 3.80.893 HOMA IR week 363.2 ± 2.04.0 ± 2.40.116 HOMA IR change−1.8 ± 1.8−1.1 ± 3.00.239Blood flow measurements Pre-ischemic BF baseline (U)23.3 ± 13.425.8 ± 14.70.350 Pre-ischemic BF week 36 (U)25.2 ± 13.426.6 ± 14.70.766 MaxBF baseline (U)81.9 ± 4899.0 ± 29.10.091 MaxBF week 36 (U)90.7 ± 4389.1 ± 32.40.697 MaxBF change (U)8.8 ± 31.5−9.9 ± 39.60.042Safety parameter Duration glucose \<3.9 baseline (min)1.5 ± 9.23.0 ± 13.10.592 Duration glucose \<3.9 week 36 (min)11.2 ± 41.413.6 ± 46.50.468 Self assessed BG \<3.1 mmol/l (*n*)4140.045 Gastrointestinal complaints (*n*)1000.001*AUC* area under the interstitial glucose curve, *incAUC* incremental area under the interstitial glucose curve of the test meal, *Mean IG* mean interstitial glucose values, *SD* standard deviation of interstitial glucose, *MAGE* mean average glucose excursions, proinsulin (pmol/l); C-peptide (nmol/l); insulin (pmol/l), *0′* start of the test meal, *120′* 2 h after the test meal; change displayed difference between week 36 and baseline, *FPG* fasting plasma glucose, *PPG* postprandial plasma glucose, *BF* blood flow, *BG* blood glucoseFig. 1Mean interstitial glucose values of the second day (including a standardized breakfast) after 36 weeks of treatment with insulin glargine or metformin

Insulin glargine treatment primarily reduced fasting hyperglycemia with first significant difference of FPG occurring after 8 weeks, mainly as an effect of stepwise insulin titration, and FPG remained significantly different between treatments until end of study (Fig. [2](#Fig2){ref-type="fig"}a). However, the between group difference did not reach significance level for change of HbA1c or PPG 2 h after the test meal (Table [2](#Tab2){ref-type="table"}) which was in agreement with the IG parameter (Fig. [1](#Fig1){ref-type="fig"}). Proinsulin as a marker of β-cell dysfunction was significantly reduced by both treatments. Of notice, this reduction was more pronounced in the glargine-treated patients in the fasting and postprandial state (Table [2](#Tab2){ref-type="table"}). Due to insulin supplementation, fasting endogenous insulin secretion (assessed by C-peptide concentration) was decreased in the glargine group, whereas postprandial endogenous insulin secretion was preserved (Table [2](#Tab2){ref-type="table"}). Consequently, the HOMA B (Table [2](#Tab2){ref-type="table"}) as well as proinsulin/C-peptide ratio after the test meal (Fig. [3](#Fig3){ref-type="fig"}) as marker of endogenous insulin secretion and therefore beta-cell function were significantly more improved by insulin glargine.Fig. 2Time course of fasting plasma glucose concentration (**a**) and body weight (**b**). Data expressed as mean ± SD. \**p* \< 0.01 (ANOVA for repeated measures)Fig. 3Fasting (0 min) and postprandial (120 min) beta-cell function assessed by proinsulin/C-peptide at baseline and study end (week 36), ^\#^ *p* \< 0.05 vs. baseline value. Data are expressed as mean ± SEM

Microvascular blood flow after 36 weeks of treatment was identical with insulin and metformin. However, the post-ischemic microvascular response improved in metformin-treated patients but not in insulin-treated patients (Table [2](#Tab2){ref-type="table"}).

Despite intensive dietary counseling, glargine-treated patients gained weight (Fig. [2](#Fig2){ref-type="fig"}b) associated with a significant increase in waist circumference of 1.1 ± 3.7 cm versus a decrease of 1.9 ± 4.1 cm in the metformin group (*p* \< 0.001).

The mean insulin dose at study end was 25.9 ± 13.2 U (0.3 ± 0.1 U/kg body weight).

Hypoglycemic episodes during BG self-monitoring---defined as any BG value \<3.1 mmol/l or symptoms of hypoglycemia---occurred rarely and were more often reported in insulin-treated patients (Table [2](#Tab2){ref-type="table"}). The mean duration of IG episodes \<3.9 mmol/l during CGM was similar between treatment groups (Table [2](#Tab2){ref-type="table"}). There was no severe hypoglycemia and only one symptomatic hypoglycemia reported in the glargine group during the study. Main adverse events in metformin-treated patients were gastrointestinal complaints, that is, discomfort, flatulence, and diarrhea (Table [2](#Tab2){ref-type="table"}). However, despite such undesired side effects of metformin, most of the patients which completed the study received the target dose of 2,000 mg metformin per day (mean dose at end of study 1,883 ± 357 mg).

Discussion {#Sec9}
==========

For the first time, our study investigated the effects of basal insulin versus metformin on glycemic control, beta-cell function, and microvascular blood flow when used as first-line treatment of type 2 diabetes. In contrast to other studies of rather short duration with various regimes of insulin application \[[@CR9], [@CR10], [@CR17], [@CR18]\], the present prospective randomized trial allowed us to compare the effects of different treatments on beta-cell function and blood flow at the same level of HbA1c and hence chronic hyperglycemia. Furthermore, all patients were drug naïve with an acceptable HbA1c (\<8.5 %) and thus presumably enough β-cell mass for improvement of beta-cell function if harmful effects of glucotoxicity can be reduced by near to normal glucose control.

As expected, we found a significantly improved control of overall interstitial glucose and FPG in both groups but insulin glargine treatment resulted in significantly lower FPG compared to metformin (Fig. [2](#Fig2){ref-type="fig"}a). We also found a more pronounced improvement of basal and postprandial beta-cell function expressed by the basal ratio of HOMA B/HOMA IR (Fig. [3](#Fig3){ref-type="fig"}a) and postprandial proinsulin/C-peptide ratio (Fig. [3](#Fig3){ref-type="fig"}b) in insulin-treated patients. However, despite these more pronounced effects on FPG and beta-cell function, we did not find a significant difference of postprandial or overall interstitial glucose load and HbA1c with insulin glargine compared to metformin at study end (Fig. [1](#Fig1){ref-type="fig"}). These results are in agreement with data from the recently published Outcome Reduction with an Initial Glargine Intervention (ORIGIN) that demonstrated a more pronounced effect of insulin glargine on FPG than on HbA1c compared to standard care \[[@CR11]\]. One possible explanation for similar effects of insulin glargine on quality of glucose control compared to metformin in the present study could be the differences in body weight gain, visceral obesity, and insulin resistance after 36 weeks of treatment. The improvement of endogenous insulin secretion after insulin treatment did not completely outweigh insulin resistance as demonstrated by insulin and plasma glucose values 2 h after the test meal.

A previous study by Alvarsson et al. \[[@CR19]\] investigated the effects of insulin treatment on stimulated C-peptide secretion in comparison with sulfonylurea over a 2-year period. The authors reported an increase in stimulated C-peptide response after insulin treatment and a decreased response after sulfonylurea. This was accompanied by a significantly lower HbA1c value after 2 years in insulin-treated patients. However, these patients had a comparable weight gain throughout the study and similar degree of insulin resistance \[[@CR19]\].

It might be possible that the improvement of beta-cell function due to insulin treatment will significantly affect progression of type 2 diabetes as demonstrated by Weng and colleagues \[[@CR10]\]. The concept of β-cell recovery due to basal insulin supplementation has been developed several years ago \[[@CR20]\]. Intermittent inhibition of endogenous insulin secretion by somatostatin has been demonstrated to increase the subsequent glucose-induced insulin secretion \[[@CR21]\]. A reduction in chronic hyperglycemia by exogenous insulin supplementation might be equally effective as demonstrated in recent trials \[[@CR10], [@CR18]\]. The latter effect can be explained by a suppression of hyperglycemia-induced reactive oxygen species \[[@CR22], [@CR23]\] or anti-apoptotic actions of insulin itself \[[@CR24]\].

We found a reduction in the post-ischemic microvascular response in insulin-treated patients compared to baseline, whereas metformin increased the post-ischemic microvascular response and hence endothelial function (Table [2](#Tab2){ref-type="table"}). Previous studies demonstrated an adversative vascular action of insulin in healthy individuals \[[@CR25]\]: Insulin modulates endothelium-dependent vascular effects through two distinct intracellular pathways. While the physiological signaling of insulin in insulin-sensitive subjects is mediated through the phosphatidylinositol-3-kinase signaling pathway resulting in the release of nitric oxide (NO) and vasodilation, pathological signaling through the mitogen-activated-protein-kinase signaling pathway in insulin-resistant subjects stimulates endothelin 1 release with subsequent vasoconstriction \[[@CR26]\]. In addition, insulin was shown to stimulate sympathetic nerve outflow which might also counter the vasodilatory effects of NO-mediated vasodilation. Therefore, the resulting vascular action of insulin depends on the vascular bed and the degree of insulin resistance, for example, insulin eventually mediates vasodilatation of the muscular vasculature in healthy individuals \[[@CR25]\]. Baseline skin blood flow is mainly regulated by sympathetic innervations and only to a lesser extent by vascular endothelium. However; post-ischemic skin blood flow is mediated by endothelium-dependent vasodilators especially prostaglandins \[[@CR27]\]. It is still under debate whether skin blood flow is a reliable measure for general endothelial function and a surrogate parameter of cardiovascular endpoints. However, there are several studies which demonstrate a significant correlation between skin blood flow and other techniques for assessment of endothelial function \[[@CR28]\], and there are interventional studies which demonstrate an improvement of skin blood flow after reduction in cardiovascular risk factors \[[@CR16], [@CR27]\]. Metformin treatment resulted in a significant reduction in body weight and an improvement of insulin sensitivity (Table [2](#Tab2){ref-type="table"}), whereas insulin increased body weight and improved insulin resistance to a smaller extend than metformin. Since insulin resistance can deteriorate endothelium-dependent vasodilatation \[[@CR29]\], it is conceivable that hyperinsulinemia in combination with a nearly unchanged insulin resistance in insulin glargine-treated patients increased the sympathetic nerve outflow without a compensatory activation of endothelium-dependent vasodilators. This finding is in agreement with previous studies which described an impaired insulin action on endothelium-dependent vasodilation in type 2 diabetic patients \[[@CR30]\]. There are conflicting results about direct vascular effects of metformin treatment itself; however, several studies demonstrated an improvement of endothelial function \[[@CR31], [@CR32]\]. Furthermore, insulin-treated patients in the present study had significantly higher fluctuations of interstitial glucose---expressed as MAGE and SD (Table [2](#Tab2){ref-type="table"}). Glucose fluctuations itself may contribute to the generation of oxidative stress and consequently to endothelial dysfunction \[[@CR33]--[@CR35]\].

Risk of hypoglycemia was not significantly increased with insulin despite HbA1c \<6.5 % equal to metformin. Several trials using insulin even in the prediabetic state reported no relevant safety concerns about hypoglycemia and only moderately increased body weight \[[@CR11], [@CR17], [@CR36], [@CR37]\]. Our study confirmed the low risk of hypoglycemia of insulin glargine treatment by CGM recordings. The higher rate of self-monitored asymptomatic hypoglycemic events (8 vs. 2) might be biased due to the higher rate of glucose self-monitoring itself in the insulin glargine-treated patients.

A limitation of our study was the rather small sample size and the higher than expected range of interstitial glucose measurements and biochemical parameter. Therefore, we cannot exclude whether the lack of a statistical significant difference in some results was due to beta errors. A further limitation may be the higher than aimed FPG value in insulin-treated patients despite a differentiated titration regimen. Main reason for this finding was the day to day variation of self-monitored glucose values. In fact, nearly all patients achieved the target value of 5.6 mmol/l of blood glucose after a median of 8 week of treatment during the study. However, we observed day by day fluctuations of fasting glucose by 1.5 mmol/l, which did not allow a further up-titration of insulin dose. A FPG at the target value might have resulted in even lower glucotoxicity and better postprandial glucose values as suggested by our previous study \[[@CR36]\]. Furthermore, we did not found a significant correlation between FPG and incremental AUC and no significantly different PPG values between insulin-treated patients who reached the target PG of 5.6 mmol/l at week 36 (*n* = 15) and metformin-treated patients (data not shown). On the other hand, as demonstrated in Fig. [2](#Fig2){ref-type="fig"}, insulin-treated patients had significantly lower fasting plasma glucose than metformin-treated patients throughout the whole study period.

Do our results imply to initiate basal insulin treatment as first-line therapy of type 2 diabetes instead of metformin? The answer is no with regard to glycemic control and endothelial function since we reach the same level of postprandial or chronic hyperglycemia with both medications, and we have no improvement of microvascular endothelial function with insulin. The answer may possible yes with regard to beta-cell function since we know from a recently large randomized trial that insulin treatment might reduce the progression of type 2 diabetes \[[@CR11]\].
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